Caribou Biosciences annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Caribou Biosciences R&D Spending Growth & History (CRBU)
Caribou Biosciences's r&d spending was $109.4M for fiscal 2025.
View full Caribou Biosciences company overviewCaribou Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $109.4M | −$20.7M | −15.92% |
| 2024 | 2024-12-31 | $130.2M | $18.1M | +16.13% |
| 2023 | 2023-12-31 | $112.1M | $29.8M | +36.29% |
| 2022 | 2022-12-31 | $82.2M | $30.0M | +57.36% |
| 2021 | 2021-12-31 | $52.3M | $17.8M | +51.79% |
| 2020 | 2020-12-31 | $34.4M | $10.8M | +45.65% |
| 2019 | 2019-12-31 | $23.6M | — | — |
Caribou Biosciences quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18.9M | −$8.8M | −31.60% |
| Q1 2026 | 2026-03-31 | $20.6M | −$14.9M | −41.99% |
| Q4 2025 | 2025-12-31 | $23.8M | −$6.6M | −21.83% |
| Q3 2025 | 2025-09-30 | $22.4M | −$8.0M | −26.36% |
| Q2 2025 | 2025-06-30 | $27.7M | −$7.8M | −21.95% |
| Q1 2025 | 2025-03-31 | $35.5M | $1.7M | +5.16% |
| Q4 2024 | 2024-12-31 | $30.5M | −$815,000 | −2.61% |
| Q3 2024 | 2024-09-30 | $30.4M | $1.8M | +6.43% |
| Q2 2024 | 2024-06-30 | $35.5M | $9.0M | +33.87% |
| Q1 2024 | 2024-03-31 | $33.8M | $8.1M | +31.42% |
| Q4 2023 | 2023-12-31 | $31.3M | $5.5M | +21.54% |
| Q3 2023 | 2023-09-30 | $28.6M | $8.6M | +42.98% |
| Q2 2023 | 2023-06-30 | $26.5M | $3.9M | +17.38% |
| Q1 2023 | 2023-03-31 | $25.7M | $11.8M | +84.64% |
| Q4 2022 | 2022-12-31 | $25.7M | $10.6M | +70.31% |
| Q3 2022 | 2022-09-30 | $20.0M | $4.2M | +26.26% |
| Q2 2022 | 2022-06-30 | $22.6M | $10.3M | +83.17% |
| Q1 2022 | 2022-03-31 | $13.9M | $3.8M | +36.98% |
| Q4 2021 | 2021-12-31 | $15.1M | $3.1M | +25.67% |
| Q3 2021 | 2021-09-30 | $15.8M | $9.7M | +156.20% |
| Q2 2021 | 2021-06-30 | $12.3M | $4.7M | +62.63% |
| Q1 2021 | 2021-03-31 | $10.2M | $1.5M | +17.64% |
| Q4 2020 | 2020-12-31 | $12.0M | — | — |
| Q3 2020 | 2020-09-30 | $6.2M | — | — |
| Q2 2020 | 2020-06-30 | $7.6M | — | — |
| Q1 2020 | 2020-03-31 | $8.6M | — | — |
Caribou Biosciences r&d spending trends
Over the last five fiscal years, Caribou Biosciences's r&d spending increased from $34.4M to $109.4M, a change of $75.0M. The latest reported quarter, Q2 2026, shows $18.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Caribou Biosciences source filings ↗